A study led by researchers at the Mass General Brigham Neuroscience Institute, presented at the Alzheimer's Association International Conference and published in JAMA, found that a blood biomarker called phosphorylated tau 217 (p-tau217) was linked to whether people with normal thinking later developed cognitive impairment. The biomarker is tied to Alzheimer's disease, and a test measuring it recently received federal clearance.
The researchers pooled data from six observational studies and clinical trials in North America, Japan, and Australia. Together they followed 2,684 older adults who showed no signs of cognitive impairment at enrollment. Participants gave blood samples for p-tau217 testing and had PET brain scans, then returned for annual assessments of memory and thinking. Some had entered the studies as early as 2004, and the latest follow-ups took place in 2025.
About 478 participants eventually developed cognitive impairment. Higher p-tau217 levels at the start of the studies went with a greater chance of later problems. Among people with very high levels, the estimated probability of impairment reached 38% within five years and 78% within 10 years. The authors noted that far fewer people had data at the 10-year mark, so those longer-range figures are less certain.
Perhaps the most notable result is that p-tau217 still predicted decline after accounting for amyloid-beta plaques seen on PET scans and for the APOE4 genetic risk factor. That suggests the test adds information beyond what those established measures provide. The researchers still do not recommend these blood tests for routine screening of people without symptoms, because no disease-modifying treatments yet exist for healthy people found to be at high risk. Lead author Rachel F. Buckley and senior author Reisa Sperling described the work as a step toward estimating an individual's risk over time, with the longer-term goal of blood testing that works like cholesterol testing for heart attack risk. The study's participants may not represent the broader population, and the analysis covered limited time windows rather than lifetime risk, so larger and more representative studies are needed.